Drug discovery without a molecular target: The road less traveled

Expert Review of Molecular Diagnostics

Volumn 7, Issue 1, 2007, Pages 1-4

  Ross Macdonald, Petra ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; GEFITINIB; IMATINIB;

CHRONIC MYELOID LEUKEMIA; DIAGNOSTIC PROCEDURE; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; EDITORIAL; HUMAN; MOLECULAR BIOLOGY; NONHUMAN;

DRUG DESIGN; DRUG THERAPY; HUMANS; SAFETY;

EID: 33846294026     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.7.1.1     Document Type: Editorial

References (26)

1. Nashed AL, Rao KW, Gulley ML. Clinical Applications of BCR-ABL Molecular Testing in Acute Leukemia. J. Mol. Diagn. 5(2), 63-72 (2003).
2. Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2), 117-125 (2002).
3. Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood (2006) (E-pub ahead of print).
4. Sawyers C. Targeted cancer therapy 432(7015), 294-297 (2004).
5. Baselga J, Rischin D, Ranson M et al. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types. J. Clin. Oncol. 20(21), 4292-4302 (2002).
6. Barten DM, Meredith JE Jr, Zaczek R, Houston JG, Albright CE Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity. Drugs R D 7(2), 87-97 (2006).
7. Searfoss GH, Jordan WH, Calligaro DO et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional {gamma}-secretase inhibitor. J. Biol. Chem. 278(46), 46107-46116 (2003).
8. Clader JW. The discovery of ezetimibe: a view from outside the receptor. J. Med. Chem. 47(1), 1-9 (2004).
9. Garcia-Calvo M, Lisnock J, Bull HG et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). PNAS 102(23), 8132-8137 (2005).
10. Moser M. Historical perspective on the management of hypertension. Am. J. Med. 80(5B), 1-11 (1986).
11. Nussberger J, Waeber B, Brunner HR. Angiotensin converting enzyme inhibition and renin inhibition. J. Hypertens. Suppl. 7(2), S75-S79 (1989).
12. Butcher EC. Can cell systems biology rescue drug discovery? Nat. Rev. Drug Discov. 4(6), 461-467 (2005).
13. Simon JS, Karnoub MC, Devlin DJ et al. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 86(6), 648-656 (2005).
14. Lackner MR, Kindt RM, Carroll PM et al. Chemical genetics identities Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell 7(4), 325-336 (2005).
15. Fitzgerald K, Tertyshnikova S, Moore L et al. Chemical genetics reveals an RGS/G-protein role in the action of a compound. PLoS Genet. 2(4), e57 (2006).
16. Smart EJ, De Rose RA, Farber SA. Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc. Natl Acad. Sci. USA 101(10), 3450-3455 (2004).
17. Kramer W, Girbig F, Corsiero D et al. Aminopeptidase N (CD13) Is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane. J. Biol. Chem. 280(2), 1306-1320 (2005).
18. Hart CP. Finding the target after screening the phenotype. Drug Discov. Today 10(7), 513-519 (2005).
19. Moffat J, Grueneberg DA, Yang X et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124(6), 1283-1298 (2006).
20. Eggert US, Kiger AA, Richter C et al. Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets. PLoS Biol. 2(12), e379 (2004).
21. Silva JM, Mizuno H, Brady A, Lucito R, Hannon GJ. RNA interference microarrays: High-throughput loss-of-function genetics in mammalian cells. PNAS 101(17), 6548-6552 (2004).
22. Parker RA, Flint OP, Mulvey R et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors Mol. Pharmacol. 67(6), 1909-1919 (2005).
23. Wei G, Twomey D, Lamb J et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance Cancer Cell 10(4), 331-342 (2006).
24. Hieronymus H, Lamb J, Ross KN et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10(4), 321-330 (2006).
25. Lamb J, Crawford ED, Peck D et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313(5795), 1929-1935 (2006).
26. Hughes TR, Marton MJ, Jones AR et al. Functional discovery via a compendium of expression profiles. Cell 102(1), 109-126 (2000).